Preparing genetically modified cells using a device that is configured for sterile processing of cells at the bedside or in a surgical room

Patent metadata

Field	Value
Publication number	US-10705091-B2
Application number	US-201916675072-A
Country	US
Kind code	B2
Filing date	Nov 5, 2019
Priority date	Dec 7, 2007
Publication date	Jul 7, 2020
Grant date	Jul 7, 2020

Abstract

The invention relates to a system, comprising: a) a sample processing unit, comprising an input port and an output port coupled to a rotating container having at least one sample chamber, the sample processing unit configured provide a first processing step to a sample or to rotate the container so as to apply a centrifugal force to a sample deposited in the chamber and separate at least a first component and a second component of the deposited sample; and b) a sample separation unit coupled to the output port of the sample processing unit, the cell separation unit comprising separation column holder ( 42 ), a pump ( 64 ) and a plurality of valves ( 1 - 11 ) configured to at least partially control fluid flow through a fluid circuitry and a separation column ( 40 ) positioned in the holder, the separation column configured to separate labeled and unlabeled components of sample flowed through the column.

First claim

What is claimed:

1. A method performed on a device,
wherein the device comprises:
a sample processing unit that includes an input port and an output port operably connected to a sample chamber, wherein the sample chamber is configured to incubate or culture cells, and is also configured to centrifuge cells contained in the chamber,
a sample separation unit that includes a separation column that is operably connected to the output port of the sample processing unit,
fluid circuitry that interconnects the sample processing unit and the sample separation unit,
a pump, and
a plurality of valves that are configured and positioned to control fluid flow through the fluid circuitry;

wherein the method comprises:
delivering a sample of cells through the input port to the sample chamber,
transferring the sample from the sample chamber through at least one open value using the pump into the sample separation unit,
separating target from non-target cells using the separation column, allowing the non-target cells to pass to a waste container,
transferring the target cells through at least one open value using the pump back to the sample chamber,
delivering to the target cells in the sample chamber a reagent that includes DNA, RNA, or virus, and cultivating or incubating the cells in a cell medium whereby genetically modified cells are produced,
centrifuging the genetically modified cells and removing a volume of the cell culture medium,
resuspending the genetically modified cells in an infusion solution, and
adjusting the cells in the infusion solution as needed to produce a pharmaceutical product having a desired volume or cell concentration for transfer to a final product container;

wherein the aforelisted steps of the method are all performed by the device in a closed sterile system whereby the pharmaceutical product transferred to the product container is suitable for cellular therapy of a patient in need thereof.

2. The method of claim 1 , wherein the closed sterile system comprises an interconnected assembly of disposable cell separation elements, wherein the assembly includes at least the sample chamber, the separation column, and the fluid circuitry.

3. The method of claim 1 , wherein the separation column retains target cells labeled with magnetic particles, while non-target cells that are not labeled with magnetic particles pass to the waste container.

4. The method of claim 1 , wherein the cells in the pharmaceutical product include at least one of the following cell types: hematopoietic stem or progenitor cells, dendritic cells, T lymphocytes, natural killer cells, and monocytes.

5. The method of claim 1 , wherein the cells in the pharmaceutical product include cells that are CD34 positive and/or CD133 positive.

6. The method of claim 1 , wherein the cells in the pharmaceutical product include a cell population selected from:
enriched regulatory T cells, wherein the sample of cells is depleted for CD8 and/or CD19 and/or CD49d, and subsequently enriched for CD25;
enriched natural killer cells, wherein the sample of cells is CD3 depleted and CD56 enriched; and
enriched blood dendritic cells, wherein the sample of cells is CD19 depleted and CD1c enriched.

7. The method of claim 1 , wherein the cells in the pharmaceutical product include:
cells have been enriched for CD34 or CD133; and/or
cells that have been depleted for CD3, CD3 and CD19, CD6, CD4 and CD8, T cell receptor (TCR) alpha or beta, or a combination of CD3, CD19, CD16, and CD14.

8. The method of claim 1 , wherein the cells in the pharmaceutical product include:
cells that have been enriched for CD14 (monocytes), CD56 (natural killer cells), CD335 (NKp46, natural killer cells), CD4 (T helper cells), CD8 (cytotoxic T cells), CD1c (BDCA-1) (blood dendritic cell subset), CD303 (BDCA-2), CD304 (BDCA-4) (blood dendritic cell subset), NKp80 (natural killer cells, gamma/delta T cells, or effector/memory T cells), 6B11 (Va24/Vb11 or invariant natural killer T cells), CD137 (activated T cells), or CD25 (regulatory T cells); and/or
cells that have been depleted for CD138 (plasma cells), CD4, CD8, CD19, CD25, CD45RA, or CD45RO.

9. The method of claim 1 , wherein the cells in the pharmaceutical product include:
cells selected from stem cells, T cells, dendritic cells, NK cells, B cells, or monocytes; and/or
cells positive for a marker selected from CD133, CD34, CD3, CD4, CD8, CD56, CD19, CD14, CD141 (BDCA-3), CD303 (BDCA-2), CD304 (BDCA-4), CD144, CD1c (BDCA-1), NKp46, NKp80, CD45RO, CD45RA, CD137, CD25, and CD138.

10. The method of claim 1 , wherein the device is configured to deliver gas to the sample chamber, and the method comprises culturing the target cells in the sample chamber.

11. The method of claim 1 , wherein the sample chamber comprises a detection window through which to monitor cells in the chamber.

12. An automated computer-controlled method performed on a device, wherein the method comprises:
delivering a sample of cells through an input port into a sample chamber on the device,
transferring the sample of cells from the sample chamber using a pump through at least one open value into a sample separation unit on the device,
separating target from non-target cells from the sample in the sample separation unit, allowing the non-target cells to pass to a waste container,
transferring the target cells using the pump through at least one open value back to the sample chamber,
delivering to the target cells in the sample chamber a reagent that includes DNA, RNA, or virus, and cultivating or incubating the cells in a cell medium whereby genetically modified cells are produced,
centrifuging the genetically modified cells and removing a volume of the cell culture medium, and
resuspending the genetically modified cells in a volume of an infusion solution to produce a pharmaceutical product;

wherein the aforelisted steps of the method are all performed by the device in a closed sterile system whereby the pharmaceutical product is suitable for cellular therapy of a patient in need thereof.

13. The method of claim 12 , wherein the closed sterile system comprises an interconnected assembly of disposable cell separation elements that includes at least the sample chamber, the separation column, and the fluid circuitry.

14. The method of claim 12 , wherein the sample separation unit comprises a separation column that separates target cells labeled with magnetic particles from non-target cells that are not labeled with magnetic particles.

15. A device for preparing a cell population for cell therapy for a patient in need thereof,
wherein the device comprises the following components:
a sample processing unit that includes an input port and an output port operably connected to a sample chamber, wherein the sample chamber is configured to incubate or culture cells, and is also configured to centrifuge cells contained in the chamber,
a sample separation unit that includes a separation column that is operably connected to the output port of the sample processing unit,
fluid circuitry that interconnects the sample processing unit and the sample separation unit,
a pump, and
a plurality of valves that control fluid flow through the fluid circuitry;

wherein the components of the device are constructed and arranged so that a user of the device can prepare the cell population according to the following procedure:
delivering a sample of cells through the input port to the sample chamber,
transferring the sample from the sample chamber through at least one open value using the pump into the sample separation unit,
separa

Assignees

• Miltenyi Biotec Gmbh
• Miltenyi Biotec Bv & Co Kg

Inventors

• Miltenyi Stefan
• Schimmelpfennig Winfried
• Lantow Holger
• Neuschaefer Niklas Elmar
• Biehl Martin
• Kabaha Eiad
• Schulz Juergen

Classifications

• A61M1/3693 Primary

  using separation based on different densities of components, e.g. centrifuging · CPC title

• A61K40/418

  Antigens related to induction of tolerance to non-self · CPC title

• A61K40/416

  Antigens related to auto-immune diseases; Preparations to induce self-tolerance · CPC title

• A61K40/46

  Viral antigens · CPC title

• A61K40/42

  Cancer antigens · CPC title